Devonian Health GroupDVHGF 49 Pretax Margin % is -459.32% as of Jan. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $3.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 941 Biotechnology companies, Devonian Health Group ranks better than 50.37% on this metric.
The historical rank and industry rank for Devonian Health Group's Pretax Margin % or its related term are showing as below:
DVHGF'
s Pretax Margin % Range Over the Past 10 Years
Min: -229.97 Med: -126.63 Max: -5.08
Current: -88.28
DVHGF's Pretax Margin % is ranked better than 50.37% of 941
companies
in the Biotechnology industry
Industry Median: -90.37
vs DVHGF: -88.28
Devonian Health Group (OTCPK:DVHGF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Devonian Health Group Pretax Margin % Related Terms
Devonian Health Group Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Devonian Health Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DVHGF) has a Pretax Margin % of -459.32% as of Jan. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #467 out of 941 companies in the Biotechnology industry, placing it in the top 49.6%.
Is Devonian Health Group's Pretax Margin % too high?
Devonian Health Group's current Pretax Margin % is -459.32%. Based on the distribution chart, Devonian Health Group ranks #467 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #467 out of 941 companies for Pretax Margin %. This puts Devonian Health Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current Pretax Margin % is -459.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current Pretax Margin % is -459.32%. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Pretax Margin % is -459.32% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Pretax Margin %: -459.32%
GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
